VTGN - VistaGen Therapeutics GAAP EPS of -$0.05 beats by $0.02 revenue of $0.36M beats by $0.11M
VistaGen Therapeutics press release (NASDAQ:VTGN): Q3 GAAP EPS of -$0.05 beats by $0.02. Revenue of $0.36M (+16.1% Y/Y) beats by $0.11M. At December 31, 2021, the Company had cash and cash equivalents of approximately $83.7 million.
For further details see:
VistaGen Therapeutics GAAP EPS of -$0.05 beats by $0.02, revenue of $0.36M beats by $0.11M